Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Provided By PR Newswire
Last update: Feb 23, 2023
—Patient Screening Complete in Adult Patients in Phase 3 ASPEN Trial of Brensocatib in Bronchiectasis; Topline Data Readout on Track for Second Quarter of 2024—
Read more at prnewswire.com175.76
+0.92 (+0.53%)
Find more stocks in the Stock Screener
INSM Latest News and Analysis
